Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CAR-T immunotherapies may have a new player

29.06.2018

Study finds that natural killer cells engineered with chimeric antigen receptors are equally effective and bring different advantages with less toxicity

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells. In a new study, published June 28 online in Cell Stem Cell, researchers at University of California San Diego School of Medicine and University of Minnesota report that similarly modified natural killer (NK) cells derived from human induced pluripotent stem cells (iPSCs) also displayed heightened activity against a mouse model of ovarian cancer.


Natural killer cells are immune cells that eliminate infected, foreign and cancer cells.

Credit: NIAID

The findings are significant, say researchers, because NK cells may offer distinct advantages over T-cells, including the ability to safely deliver engineered NK cells in an off-the-shelf manner without patient matching.

"One of the main challenges of immunotherapy has been the clinical manufacture of modified cells," said senior author Dan Kaufman, MD, PhD, professor of medicine in the Division of Regenerative Medicine and director of cell therapy at UC San Diego School of Medicine. "We've shown that you can engineer iPSCs, create chimeric antigen receptor-expressing NK cells to better target refractory cancers that have resisted other treatments."

CAR-T cell-based immunotherapies have garnered considerable attention and investment in recent years. T-cells, a type of white blood cell, are extracted from a patient's blood, genetically modified with a chimeric antigen receptor (the CAR) to bind with a certain protein on the patient's cancer cells, grown in large numbers in a laboratory and then infused into the patient.

"NK cells offer significant advantages as they don't have to be matched to a specific patient," said Kaufman. "Additionally, one batch of iPSC-derived NK cells can be potentially used to treat thousands of patients, which means we can develop standardized, 'off-the-shelf' treatments and use these in combination with other cancer drugs."

Early testing of CAR-T therapies have shown promise -- and sometimes dramatic success -- but there are distinct limitations. First, cells must be isolated from each individual -- a process that takes significant time and money. Additionally, since T-cell therapy is designed to work only for that patient, some patients may not be able to have T cells collected, or they may not have time for this process before the tumor progresses. This means some patients who could potentially benefit will not be able to get CAR-T cell-based therapies.

Moreover, Kaufman noted CAR-T therapies have been associated with sometimes severe toxicities or adverse effects, including unexpected organ damage and death. Previous research by Kaufman and others suggest NK cells do not trigger similar toxicities -- and the latest paper found few adverse effects in mouse models.

"NK cells may just be safer to use," Kaufman said. Kaufman is now collaborating with scientists from San Diego-based Fate Therapeutics to scale up processes to progress to clinical trials.

In their research, the researchers tested CAR NK cells derived from human iPSCs in an ovarian cancer xenograft mouse model, comparing their anti-tumor activity against other versions of NK cells and CAR-T cells. The former demonstrated similar activity to CAR-T cells, but with less toxicity. Kaufman said data indicated ovarian cancer was a good first target, but that other solid tumors, such as breast cancer, brain tumors, and colon cancers, as well as blood cell cancers such as leukemias are also likely to be suitable targets of iPSC-derived NK cells.

###

Co-authors of the study include: Ye Li, UC San Diego; and David Hermanson and Branden S. Moriarty, University of Minnesota, Minneapolis.

Media Contact

Scott LaFee
slafee@ucsd.edu
858-249-0456

 @UCSanDiego

http://www.ucsd.edu 

Scott LaFee | EurekAlert!

Further reports about: CAR blood cell cancer cells immunotherapies mouse model ovarian ovarian cancer tumors

More articles from Health and Medicine:

nachricht Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine

nachricht Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

Im Focus: Coping with errors in the quantum age

Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly

The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

The dawn of a new era for genebanks - molecular characterisation of an entire genebank collection

13.11.2018 | Life Sciences

Fish recognize their prey by electric colors

13.11.2018 | Life Sciences

Ultrasound Connects

13.11.2018 | Awards Funding

VideoLinks
Science & Research
Overview of more VideoLinks >>>